NasdaqGM:SPRYBiotechs
Does China’s First Community Epinephrine Spray Approval Reshape the Bull Case for ARS Pharmaceuticals (SPRY)?
ARS Pharmaceuticals recently received approval from China’s National Medical Products Administration for neffy, its epinephrine nasal spray, and entered an exclusive commercialization agreement with Shanghai-based Pediatrix Therapeutics.
This approval makes neffy the first epinephrine treatment cleared for community use outside hospitals in China, potentially reshaping ARS’s geographic and product diversification profile.
We’ll now examine how China’s first-in-kind community-use approval for...